Community Practice Connections : Highlights of ASH : New Frontiers in the Management of AML Treatment : The Emerging Role of Targeted Therapies
WebcastFaculty
OVERVIEW
Community Practice Connections : Highlights of ASH : New Frontiers in the Management of AML Treatment : The Emerging Role of Targeted Therapies is organized by Physicians Education Resource, LLC (PER) and will be held during Mar 31, 2017 - Mar 31, 2018.
The target audience for this medical event is oncologists, hematologists, nurses, physician assistants, fellows and other healthcare professionals interested in emerging data and advances in treatment of AML. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits.
Conference Objectives are :
• Determine contemporary strategies for the management of AML and clinically unmet needs in the field.
• Discuss activating mutations identified in AML that provide the rationale for the development of targeted mechanistic approaches.
• Explain recent clinical trial results concerning novel targeted strategies to manage AML and next steps in the field with single agent and combination trials.
• Place recent clinical trial findings on targeted strategies in the context of evolving treatment paradigms and how targeted approaches may be used to optimize outcomes in AML.
Additional details will be posted as soon as they are available.
The target audience for this medical event is oncologists, hematologists, nurses, physician assistants, fellows and other healthcare professionals interested in emerging data and advances in treatment of AML. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits.
Conference Objectives are :
• Determine contemporary strategies for the management of AML and clinically unmet needs in the field.
• Discuss activating mutations identified in AML that provide the rationale for the development of targeted mechanistic approaches.
• Explain recent clinical trial results concerning novel targeted strategies to manage AML and next steps in the field with single agent and combination trials.
• Place recent clinical trial findings on targeted strategies in the context of evolving treatment paradigms and how targeted approaches may be used to optimize outcomes in AML.
Additional details will be posted as soon as they are available.
SPECIALITIES
Haematology
Quick Links